| Literature DB >> 30862719 |
Zeynep Madak-Erdogan1,2,3,4,5,6, Shoham Band7, Yiru C Zhao7, Brandi P Smith7, Eylem Kulkoyluoglu-Cotul7, Qianying Zuo7, Ashlie Santaliz Casiano2, Kinga Wrobel7, Gianluigi Rossi8, Rebecca L Smith8, Sung Hoon Kim9, John A Katzenellenbogen9, Mariah L Johnson10, Meera Patel10, Natascia Marino10,11, Anna Maria V Storniolo10,11, Jodi A Flaws12.
Abstract
Obesity is a risk factor for postmenopausal estrogen receptor alpha (ERα)-positive (ER+) breast cancer. Molecular mechanisms underlying factors from plasma that contribute to this risk and how these mechanisms affect ERα signaling have yet to be elucidated. To identify such mechanisms, we performed whole metabolite and protein profiling in plasma samples from women at high risk for breast cancer, which led us to focus on factors that were differentially present in plasma of obese versus nonobese postmenopausal women. These studies, combined with in vitro assays, identified free fatty acids (FFA) as circulating plasma factors that correlated with increased proliferation and aggressiveness in ER+ breast cancer cells. FFAs activated both the ERα and mTOR pathways and rewired metabolism in breast cancer cells. Pathway preferential estrogen-1 (PaPE-1), which targets ERα and mTOR signaling, was able to block changes induced by FFA and was more effective in the presence of FFA. Collectively, these data suggest a role for obesity-associated gene and metabolic rewiring in providing new targetable vulnerabilities for ER+ breast cancer in postmenopausal women. Furthermore, they provide a basis for preclinical and clinical trials where the impact of agents that target ERα and mTOR signaling cross-talk would be tested to prevent ER+ breast cancers in obese postmenopausal women. SIGNIFICANCE: These findings show that obesity-associated changes in certain blood metabolites rewire metabolic programs in cancer cells, influence mammary epithelial cell tumorigenicity and aggressiveness, and increase breast cancer risk. ©2019 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30862719 DOI: 10.1158/0008-5472.CAN-18-2849
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701